Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L. Leddon, Trisha M. Wise‐Draper, Shuchi Gulati et al.|Clinical Cancer Research|2022Cited by 26
Pathologic Features Associated With Molecular Subtypes of Well-Differentiated Thyroid CancerAlice L. Tang, David L. Steward, Richard T. Kloos et al.|Endocrine Practice|2020Cited by 20
Proton Treatment Suppresses Exosome Production in Head and Neck Squamous Cell CarcinomaAmeet A. Chimote, Laura Conforti, Maria Lehn et al.|Cancers|2024Cited by 7
Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.Jennifer L. Leddon, Trisha M. Wise‐Draper, Sulsal Haque et al.|Journal of Clinical Oncology|2021Cited by 5
Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).Eejung Kim, Trisha M. Wise‐Draper, Sarah Palackdharry et al.|Journal of Clinical Oncology|2018Cited by 4